Israel's Medical Cannabis Exports: Small Volumes, Big Trade Fights

September 17, 2026

Photo by Mediamodifier via Unsplash.

Walk into a pharmacy or a distribution warehouse in Israel and the paperwork tells you more about the country's cannabis industry than any press release does. This is a market built on permits, stamps, and inspection reports -- three separate government bodies have to sign off before a gram of flower crosses a border in either direction. And behind that bureaucracy sits a genuinely strange dynamic: roughly 130,000 domestic patients rely on a steady supply of imported cannabis, about a dozen major importers compete to bring it in, and something like 15 domestic growers are fighting over what's left of the local market while trying to convince regulators that cheap foreign product is squeezing them out.

None of this is abstract policy chatter. In the past year it's produced a formal anti-dumping complaint against Canada, a regulatory reform meant to bring Israeli certification in line with European standards, and export numbers that, frankly, look small next to what Germany and Canada are moving. Israel built one of the world's most credentialed medical cannabis systems -- academic research going back decades, a licensing regime other countries study -- and yet it remains, by volume, a buyer more than a seller. Understanding why requires looking at both ends of the pipeline: how Israel opened its export lane, and why the fight over imports has gotten so heated that it's now a formal trade dispute.

How Israel Built Its Export Pipeline

Photo by Shalev Cohen via Unsplash.

Israel didn't back into a cannabis export industry -- it engineered one, deliberately and slowly, over the better part of a decade. The Knesset approved the underlying export framework in 2018, but approval on paper and an operational pipeline are different things. It took until 2019 for the Israel Medical Cannabis Agency (IMCA), the regulatory body that oversees the entire domestic program, to actually stand up the systems needed to process exporters rather than just domestic licensees.

The real unlock came in May 2020, when then-Economy Minister Eli Cohen signed the Free Export Order, formally implementing a cabinet decision that had been sitting on the books since January 2019. That's a sixteen-month gap between political agreement and legal execution, which tells you something about how cautiously Israel has approached opening this market -- health ministries and police both wanted assurances before product started moving internationally. Even once the order took effect, exporters weren't allowed to simply apply for permits immediately; there was a mandatory 30-day waiting window built in, presumably to let the administrative machinery catch up with the new legal reality.

What emerged is a three-layer approval structure that remains unusually demanding by global standards. A grower or processor first needs IMC-GMP certification -- Israel's own manufacturing quality standard for medical cannabis. Then comes Ministry of Health licensing, which evaluates the product and the facility against pharmaceutical-grade criteria. Finally, Israel Police has to sign off, a holdover from the fact that cannabis remains a controlled substance requiring law enforcement clearance for movement across borders. Getting through all three has historically taken months.

That started to change in August 2023. On August 7 of that year, Israel announced a reform package explicitly designed to simplify the export approval chain, and the headline change was aligning Israeli certification standards with the EU-GMP standard used across Europe. That's not a cosmetic tweak -- EU-GMP is effectively the passport European buyers require, and matching it meant Israeli exporters no longer needed a separate, redundant certification just to sell into the continent's biggest medical cannabis markets.

The Numbers Tell a Modest Story

Photo by Budding . via Unsplash.

Here's where the story gets less impressive on paper. Israel exported roughly 7.5 tonnes of medical cannabis in the first nine months of 2025, with Portugal and Germany taking most of it. That's a real number, and it reflects a functioning export program -- but it's not a lot of cannabis. Put it next to Canada or Germany's own export figures over a comparable stretch and Israel looks like a niche supplier rather than a serious player in the global medical cannabis trade.

The imbalance runs the other direction too, and more sharply. Israel imports far more cannabis than it ships out, and for years Canada alone has supplied around 80% of those imports. That's a striking concentration -- four out of every five grams of imported medical cannabis entering Israel has historically come from Canadian growers, which is precisely the dynamic now fueling the trade dispute detailed further down.

The demand side of that equation isn't mysterious. IMCA oversees roughly 130,000 active medical cannabis patients inside Israel, a patient population built up over nearly two decades of clinical use predating most Western medical cannabis programs. That's a steady, prescription-driven demand base, and domestic cultivation alone hasn't been enough to satisfy it -- hence the reliance on imports even as Israel simultaneously tries to grow its export business elsewhere.

There's also a shift happening on the sourcing side worth flagging: Israel has lost ground as a buyer of Portuguese-grown cannabis. As EU-GMP compliance becomes the baseline expectation across the industry rather than a competitive edge, Portugal's growers have less reason to prioritize the Israeli market specifically, and Israeli buyers face more competition from European purchasers for the same EU-GMP-certified product. It's a reminder that certification alignment cuts both ways -- it opens doors for Israeli exporters in Europe, but it also erodes whatever special relationship Israeli importers once had with specific European suppliers.

Israel vs. the World's Export Leaders

Canada's 2025 medical cannabis exports (275.3 tonnes) dwarf those of Germany (66.3 tonnes) and Israel (7.5 tonnes), highlighting Israel's much smaller current export volume as it moves to approve broader exports.

Numbers make the size gap obvious fast. Canadian medical cannabis exports jumped more than 250% year-on-year, reaching 275,343 kilograms in 2025. That's not organic, incremental growth -- that's a country's export sector fundamentally repositioning itself as a global supplier, and it dwarfs Israel's entire nine-month export total by a factor of more than 35.

Germany tells a similar story from a different angle. German producers alone exported 66,305 kilograms in just the first half of 2026 -- not a full year, half of one. That's roughly nine times Israel's nine-month total, achieved in six months, by a country that until fairly recently was known primarily as a cannabis importer rather than an exporter.

Set against those figures, Israel's 7.5 tonnes over nine months looks modest even when you account for the country's smaller population and its comparatively young export program. Israel has roughly 9.5 million people, a fraction of the populations of Germany and Canada, so a straight per-capita comparison softens the gap somewhat -- but it doesn't close it. Canada's and Germany's growth curves reflect industrial-scale cultivation operations and export infrastructure that Israel, with its smaller land base and more tightly regulated licensing regime, simply hasn't built at the same scale.

That gap goes a long way toward explaining Israel's current posture in the global market. Rather than positioning itself as a volume competitor to Canadian or German growers, Israel has leaned into being a demanding, quality-focused import market -- one with sophisticated patients, a mature clinical infrastructure, and regulators willing to scrutinize supplier pricing closely. The anti-dumping complaint against Canada, which follows, is really an extension of that identity: a market that knows exactly what it's buying and isn't shy about pushing back when it thinks the terms are unfair.

The Canada Dumping Fight Reopens

Photo by frank mckenna via Unsplash.

On August 5, 2026, Israel formally reopened an anti-dumping investigation into Canadian medical cannabis imports -- a case that had, on paper, already been closed. That prior investigation ended abruptly on July 29, 2026, not because the underlying complaint lacked merit but on a procedural technicality: Israel had failed to properly notify Canadian authorities as required. A week later, the notice went back out, and the clock restarted.

The investigation period under review runs from July 2025 to June 2026, and the trade figures at its center are stark. Canada exported CAD$107,954,748 worth of cannabis to Israel during that window -- compare that to just CAD$37,045,648 from every other country combined. Canada alone accounted for roughly three-quarters of Israel's total cannabis import value in that period, a concentration that mirrors the long-standing 80% supply share mentioned earlier and gives domestic growers a single, clear target for their complaint.

Twelve Israeli importers are named in the filing, a list that reads like a who's-who of the country's medical cannabis distribution sector: Canndoc, Tikun Olum, BOL Pharma, Together Pharma, and IMC among them. These are the companies that have built their business models around bringing in Canadian flower at competitive prices -- which is exactly what's now under scrutiny.

Backing the complaint are about 15 domestic growers, representing roughly 80% of the local cultivation market, who argue that Canadian imports are being sold at prices below what it costs to produce comparable cannabis domestically -- the classic definition of dumping under trade law. Foreign exporters named in or affected by the case have been given until September 7, 2026 to respond to a formal questionnaire, the standard next step in any anti-dumping proceeding, where companies have to disclose cost structures and pricing data to demonstrate their prices reflect genuine market conditions rather than predatory undercutting.

What This Means for Growers and Patients

Strip away the trade-law jargon and the growers' argument is straightforward: they can't compete on price against Canadian flower grown at massive scale and shipped in under favorable terms, and every dollar Canadian imports undercut them by is a dollar Israeli cultivators don't see. With roughly 15 growers holding about 80% of the domestic cultivation market, this isn't a fringe complaint -- it's coming from the industry's core, and it's been building for years as Canada's 80% import share has held steady or grown.

If the investigation concludes with tariffs or anti-dumping duties imposed on Canadian product, the pressure shifts to the importers. Companies like Canndoc and Together Pharma built distribution businesses around sourcing Canadian flower at competitive rates; add a duty on top of that, and those costs don't just disappear -- they get passed along, eventually, to the 130,000 patients who depend on a stable, affordable supply. That's the real tension in this case: protecting domestic growers and keeping patient costs low aren't necessarily compatible goals, and Israeli regulators will have to decide which one takes priority if the investigation results in formal action.

Meanwhile, Israel's push toward EU-GMP alignment tells you where the country wants to be in five years -- a credible exporter into Europe's largest medical cannabis markets, competing on quality and clinical pedigree rather than on the sheer volume Canada and Germany can produce. But that ambition sits awkwardly next to a home market that remains structurally import-dependent, with domestic growers unable to meet demand on price or volume alone.

What makes this whole episode worth watching isn't the tonnage -- it's the disproportion. A country exporting a few thousand kilograms a year has managed to generate a formal international trade dispute with Canada, a producer moving over a quarter-million kilograms annually. That's what happens when a small market is also a sophisticated, well-organized one: size doesn't determine leverage, and Israel's growers clearly believe their complaint carries weight regardless of how modest their collective export numbers look next to the industry's giants.

The anti-dumping case will likely take months to resolve, and its outcome matters less for Israel's global standing than a quieter question running underneath it: does EU-GMP alignment actually translate into European market share for Israeli exporters, or does it simply keep them competitive enough to avoid falling further behind? Portugal and Germany are already buying Israeli product, but at 7.5 tonnes over nine months, there's a lot of room to grow before Israel registers as more than a rounding error next to Canadian or German export volumes.

The more likely near-term outcome is that Israel settles further into its current identity -- a demanding, clinically sophisticated import market with a patient base that regulators and growers alike take seriously, rather than a volume exporter chasing Canada's or Germany's numbers. That's not necessarily a failure. A market with 130,000 patients, rigorous certification standards, and the institutional confidence to challenge a major trading partner over pricing has real influence, even if its export tonnage doesn't show it. Whether that influence eventually converts into export growth is the thing worth checking back on in a year.